



Cite this: *RSC Adv.*, 2017, 7, 17367

Further correction: Synthesis and characterization of TPGS–gemcitabine prodrug micelles for pancreatic cancer therapy

Vaibhav Khare,^{ab} Wejdan Al. Sakarchi,^a Prem N. Gupta,^b Anthony D. M. Curtis^a and Clare Hoskins^{*a}

DOI: 10.1039/c7ra90041d

www.rsc.org/advances

Further correction for 'Synthesis and characterization of TPGS–gemcitabine prodrug micelles for pancreatic cancer therapy' by Vaibhav Khare *et al.*, *RSC Adv.*, 2016, 6, 60126–60137.

The structures shown in Fig. 1 of the previous correction to the original manuscript were incomplete. The corrected Fig. 1 is shown below.




Fig. 1 A schematic representation of the reaction involved in the synthesis of tocopherol polyethylene glycol succinate 1000 (TPGS)–gemcitabine prodrug.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

^aInstitute of Science and Technology in Medicine, Keele University, Keele, Staffordshire, ST55BJ, UK. E-mail: c.hoskins@keele.ac.uk

^bFormulation and Drug Delivery Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, India 180001

